The Presence and Severity of Chronic Kidney Disease Predicts All-Cause Mortality in Type 1 Diabetes
Open accessThe DOI matches its Crossref record; 49 of the 49 references it cites were found in a registry or an index.
Abstract
OBJECTIVES: This study aimed to identify clinical features associated with premature mortality in a large contemporary cohort of adults with type 1 diabetes. RESEARCH DESIGN AND METHODS: The Finnish Diabetic Nephropathy (FinnDiane) study is a national multicenter prospective follow-up study of 4,201 adults with type 1 diabetes from 21 university and central hospitals, 33 district hospitals, and 26 primary health care centers across Finland. RESULTS: During a median 7 years of follow-up, there were 291 deaths (7%), 3.6-fold (95% CI 3.2–4.0) more than that observed in the age- and sex-matched general population. Excess mortality was only observed in individuals with chronic kidney disease. Individuals with normoalbuminuria showed no excess mortality beyond the general population (standardized mortality ratio [SMR] 0.8, 95% CI 0.5–1.1), independent of the duration of diabetes. The presence of microalbuminuria, macroalbuminuria, and end-stage kidney disease was associated with 2.8, 9.2, and 18.3 times higher SMR, respectively. The increase in mortality across each stage of albuminuria was equivalent to the risk conferred by preexisting macrovascular disease. In addition, the glomerular filtration rate was independently associated with mortality, such that individuals with impaired kidney function, as well as those demonstrating hyperfiltration, had an increased risk of death. CONCLUSIONS: An independent graded association was observed between the presence and severity of kidney disease and mortality in a large contemporary cohort of individuals with type 1 diabetes. These findings highlight the clinical and public health importance of chronic kidney disease and its prevention in the management of type 1 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Diabetic nephropathy, whether manifesting as microalbuminuria, macroalbuminuria, or a reduced glomerular filtration rate progressively augments the overall risk of macrovascular complications.118”
From Type 1 diabetes (2018) · cites this paper as [118]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,10,11).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [11]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, UACR is a continuous measurement, and differences within the normal and abnormal ranges are associated with kidney and cardiovascular outcomes (6,11,12).”
From 11. Chronic Kidney Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [12]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Toprak, O., Kurt, H., Sarı, Y., Şarkış, C., Us, H., & Kırık, A. (2017) · Kidney and Blood Pressure Research · doi:10.1159/000468530 · Cited by 29,627
Levey, A. S., Coresh, J., Bolton, K., Culleton, B. F., Harvey, K. S., Ikizler, T. A., Johnson, C. A., Kausz, A., Kimmel, P. L., Kusek, J. W., et al. (2002) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 11,633
Proportional hazards tests and diagnostics based on weighted residuals
GRAMBSCH, P. M., & THERNEAU, T. M. (1994) · Biometrika · doi:10.1093/biomet/81.3.515 · Cited by 5,885 · cited 3×
“9* Any retinopathy 76 (29)† 1,313 (50) 420 (93)† 290 (99)† Retinopathy requiring laser therapy 27 (10)† 683 (25) 360 (78)† 288 (97)† Current smoker 98 (37)† 614 (24) 95 (22) 49 (16)† Established macrovascular disease 31 (11)† 123 (5) 116 (25)† 138 (47)† Macroalbuminuria 2 (3)† 210 (8) 338 (73)† N/A Microalbuminuria 2…”
MethodIntensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes
(2005) · New England Journal of Medicine · doi:10.1056/nejmoa052187 · Cited by 5,138
Goodpasture syndrome during the course of a Schönlein-Henoch purpura
Carreras, L., Poveda, R., Bas, J., Mestre, M., Rama, I., & Carrera, M. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2002.32799 · Cited by 1,474
Albuminuria reflects widespread vascular damage: The Steno hypothesis
Deckert, T., Feldt-Rasmussen, B., Borch-Johnsen, K., Jensen, T., & Kofoed-Enevoldsen, A. (1989) · Diabetologia · doi:10.1007/bf00285287 · Cited by 1,400
Doqi, K. (2002) · American Journal of Kidney Diseases · Cited by 1,285
Global guideline for type 2 diabetes
(2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2012.10.001 · Cited by 1,064
Conditioning Diagnostics: Collinearity and Weak Data in Regression
Goldstein, R. (1993) · Technometrics · doi:10.1080/00401706.1993.10484997 · Cited by 911
(2004) · doi:10.1177/0049124103262065 · Cited by 906
Cited by
Items 101–200 of 651
The trials and tribulations of determining HbA1c targets for diabetes mellitus
Klein, K. R., & Buse, J. B. (2020) · Nature Reviews Endocrinology · doi:10.1038/s41574-020-00425-6 · Cited by 97
Incidence of End-Stage Renal Disease in Patients With Type 1 Diabetes
Helve, J., Sund, R., Arffman, M., Harjutsalo, V., Groop, P., Grönhagen‐Riska, C., & Finne, P. (2017) · Diabetes Care · doi:10.2337/dc17-2364 · Cited by 94
Self-citationSu, K., Deng, D., Wu, X., Song, Y., Song, Y., Wang, X., Zhang, Z., Li, J., Yan, Z., Shang, X., et al. (2023) · Chemical Engineering Journal · doi:10.1016/j.cej.2023.147646 · Cited by 97
Tikkanen-Dolenc, H., Wadén, J., Forsblom, C., Harjutsalo, V., Thorn, L. M., Saraheimo, M., Elonen, N., Tikkanen, H. O., & Groop, P.-H. (2017) · Diabetes Care · doi:10.2337/dc17-0615 · Cited by 93
Self-citationEpidemiology of Type 1 Diabetes
Vanderniet, J. A., Jenkins, A. J., & Donaghue, K. C. (2022) · Current Cardiology Reports · doi:10.1007/s11886-022-01762-w · Cited by 109
Management of Type 1 Diabetes in Older Adults
Dhaliwal, R., & Weinstock, R. S. (2014) · Diabetes Spectrum · doi:10.2337/diaspect.27.1.9 · Cited by 80
Hyperglycemia-induced Renal P2X7 Receptor Activation Enhances Diabetes-related Injury
Menzies, R. I., Booth, J. W. R., Mullins, J. J., Bailey, M. A., Tam, F. W. K., Norman, J. T., & Unwin, R. J. (2017) · EBioMedicine · doi:10.1016/j.ebiom.2017.04.011 · Cited by 96
“Diabetic nephropathy is a unique predictor of mortality in both insulin-dependent and -independent diabetes (Afkarian et al., 2013; Groop et al., 2009).”
Tofte, N., Suvitaival, T., Ahonen, L., Winther, S. A., Theilade, S., Frimodt-Møller, M., Ahluwalia, T. S., & Rossing, P. (2019) · Scientific Reports · doi:10.1038/s41598-019-52916-w · Cited by 87
Time trends in mortality rates in type 1 diabetes from 2002 to 2011
Jørgensen, M. E., Almdal, T., & Carstensen, B. (2013) · Diabetologia · doi:10.1007/s00125-013-3025-7 · Cited by 89
“Most of the excess mortality in early-onset type 1 diabetes is due to long-term complications, particularly nephropathy [2, 3], but knowledge about mortality rates in late-onset and elderly type 1 diabetes is scarce.”
BackgroundPanduru, N. M., Sandholm, N., Forsblom, C., Saraheimo, M., Dahlström, E. H., Thorn, L. M., Gordin, D., Tolonen, N., Wadén, J., Harjutsalo, V., et al. (2015) · Diabetes Care · doi:10.2337/dc14-2330 · Cited by 85
Self-citationThe Gut-Kidney Axis: Putative Interconnections Between Gastrointestinal and Renal Disorders
Lehto, M. J., & Groop, P. (2018) · Frontiers in Endocrinology · doi:10.3389/fendo.2018.00553 · Cited by 89
Self-citationToyama, T., Furuichi, K., Ninomiya, T., Shimizu, M., Hara, A., Iwata, Y., Kaneko, S., & Wada, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0071810 · Cited by 87
Structural Renal Changes in Obesity and Diabetes
Amann, K., & Benz, K. (2013) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2012.12.003 · Cited by 86
Lewis, J. S., Stewart, J. M., Marshall, G. P., Carstens, M. R., Zhang, Y., Dolgova, N. V., Xia, C., Brusko, T. M., Wasserfall, C. H., Clare-Salzler, M. J., et al. (2019) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.9b00332 · Cited by 89
The pathobiology of diabetic vascular complications—cardiovascular and kidney disease
Gray, S. P., & Jandeleit-Dahm, K. A. M. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-014-1146-1 · Cited by 96
“focus on the early stages of disease development are needed in order to prevent disease development and progression [38].”
BackgroundGarofolo, M., Gualdani, E., GIANNARELLI, R., Aragona, M., Campi, F., Lucchesi, D., Daniele, G., Miccoli, R., Francesconi, P., Prato, S. D., et al. (2019) · Cardiovascular Diabetology · doi:10.1186/s12933-019-0961-7 · Cited by 93
New Therapies for Diabetic Kidney Disease
Himmelfarb, J., & Tuttle, K. R. (2013) · New England Journal of Medicine · doi:10.1056/nejme1313104 · Cited by 84
Frequent and intensive physical activity reduces risk of cardiovascular events in type 1 diabetes
on behalf of the FinnDiane Study Group, Tikkanen-Dolenc, H., Wadén, J., Forsblom, C. M., Harjutsalo, V., Thorn, L. M., Saraheimo, M., Elonen, N., Rosengård‐Bärlund, M., Gordin, D., et al. (2016) · Diabetologia · doi:10.1007/s00125-016-4189-8 · Cited by 90
Self-citationSphingomyelin is associated with kidney disease in type 1 diabetes (The FinnDiane Study)
Mäkinen, V., Tynkkynen, T., Soininen, P., Forsblom, C. M., Peltola, T., Kangas, A. J., Groop, P., & Ala‐Korpela, M. (2011) · Metabolomics · doi:10.1007/s11306-011-0343-y · Cited by 92
Self-citationJesudason, D. R., Pedersen, E., & Clifton, P. M. (2013) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.113.060889 · Cited by 91
Harjutsalo, V., Pongrac Barlovic, D., & Groop, P.-H. (2021) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(21)00172-8 · Cited by 82
Self-citationLeti, F., & DiStefano, J. K. (2017) · Genes · doi:10.3390/genes8080207 · Cited by 85
Podocyte Bioenergetics in the Development of Diabetic Nephropathy: The Role of Mitochondria
Audzeyenka, I., Bierżyńska, A., & Lay, A. C. (2021) · Endocrinology · doi:10.1210/endocr/bqab234 · Cited by 87
on behalf of the FinnDiane Study Group, Thomas, M. C., Söderlund, J., Lehto, M. J., Mäkinen, V., Moran, J. L., Cooper, M. E., Forsblom, C. M., & Groop, P. (2011) · Diabetologia · doi:10.1007/s00125-011-2186-5 · Cited by 82
“Study sample The FinnishDiabetic Nephropathy (FinnDiane) Study has been described in detail in previous publications [18–20].”
BackgroundMethodSelf-citationCardiovascular risk in double diabetes mellitus—when two worlds collide
Cleland, S. J. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2012.47 · Cited by 92
Groop, P.-H., Dandona, P., Phillip, M., Gillard, P., Edelman, S., Jendle, J., Xu, J., Scheerer, M. F., Thoren, F., Iqbal, N., et al. (2020) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(20)30280-1 · Cited by 79
Self-citationGordin, D., Forsblom, C. M., Panduru, N. M., Thomas, M. C., Bjerre, M., Soro‐Paavonen, A., Tolonen, N., Sandholm, N., Flyvbjerg, A., Harjutsalo, V., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0065 · Cited by 78
Self-citationThorn, L. M., Gordin, D., Harjutsalo, V., Hägg-Holmberg, S., Masar, R., Saraheimo, M., Tolonen, N., Wadén, J., Groop, P., & Forsblom, C. M. (2015) · Diabetes Care · doi:10.2337/dc15-0641 · Cited by 88
Self-citationSodium and Its Role in Cardiovascular Disease – The Debate Continues
Kong, Y. W., Baqar, S., Jerums, G., & Ekinci, E. I. (2016) · Frontiers in Endocrinology · doi:10.3389/fendo.2016.00164 · Cited by 86
“Moreover, in these individuals, there was also an inverse association between sodium intake and the development of end-stage renal disease (144), which is associated with a significantly increased mortality risk (163).”
BackgroundLa, Z., Shergis, J. L., Yang, L., Zhang, A. L., Guo, X., Zhang, L., Zhou, S., Zeng, L., Mao, W., & Xue, C. C. (2019) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2019.111921 · Cited by 79
Targeting oxidative stress and anti-oxidant defence in diabetic kidney disease
Østergaard, J. A., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2020) · Journal of Nephrology · doi:10.1007/s40620-020-00749-6 · Cited by 77
Diabetes Mellitus and Heart Failure
Triposkiadis, F. K., Xanthopoulos, A. V., Bargiota, Α., Kitai, T., Katsiki, N., Farmakis, D. T., Skoularigis, J. S., Starling, R. C., & Iliodromitis, E. K. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10163682 · Cited by 81
The Susceptibility Genes in Diabetic Nephropathy
Wei, L., Xiao, Y., Li, L., Xiong, X., Han, Y., Zhu, X., & Sun, L. (2018) · Kidney Diseases · doi:10.1159/000492633 · Cited by 78
Nair, V., Komorowsky, C. V., Weil, E. J., Yee, B., Hodgin, J. B., Harder, J. L., Godfrey, B., Ju, W., Boustany, C., Schwarz, M., et al. (2017) · Kidney International · doi:10.1016/j.kint.2017.08.013 · Cited by 75
Functional methylome analysis of human diabetic kidney disease
Park, J., Guan, Y., Sheng, X., Gluck, C. A., Seasock, M. J., Hakimi, A. A., Qiu, C., Pullman, J. M., Verma, A. K., Li, H., et al. (2019) · JCI Insight · doi:10.1172/jci.insight.128886 · Cited by 74
Early microvascular complications in type 1 and type 2 diabetes: recent developments and updates
Tommerdahl, K. L., Shapiro, A. L. B., Nehus, E. J., & Bjornstad, P. (2021) · Pediatric Nephrology · doi:10.1007/s00467-021-05050-7 · Cited by 86
Sandholm, N., Cole, J. B., Nair, V., Sheng, X., Liu, H., Ahlqvist, E., van Zuydam, N., Dahlström, E. H., Fermin, D., Smyth, L. J., et al. (2022) · Diabetologia · doi:10.1007/s00125-022-05735-0 · Cited by 68
Self-citationCardiovascular Disease and Diabetic Kidney Disease
Maqbool, M., Cooper, M. E., & Jandeleit-Dahm, K. A. M. (2018) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2018.02.003 · Cited by 78
Improved prognosis of diabetic nephropathy in type 1 diabetes
Andrésdóttir, G., Jensen, M. L., Carstensen, B., Parving, H., Hovind, P. H., Hansen, T. W., & Rossing, P. R. (2014) · Kidney International · doi:10.1038/ki.2014.206 · Cited by 75
Barlovič, D. P., Harjutsalo, V., Sandholm, N., Forsblom, C. M., Groop, P., & on behalf of the FinnDiane Study Group (2020) · Diabetologia · doi:10.1007/s00125-020-05201-9 · Cited by 76
“Diabetic kidney disease (DKD) is a fundamental risk factor for CVD in individuals with type 1 diabetes [1].”
BackgroundSelf-citationInsulin Sensitivity and Albuminuria: The RISC Study
Pilz, S., Rutters, F., Nijpels, G., Stehouwer, C. D. A., Højlund, K., Nolan, J. J., Balkau, B., Dekker, J. M., & the RISC Investigators (2014) · Diabetes Care · doi:10.2337/dc13-2573 · Cited by 72
Syreeni, A., El-Osta, A., Forsblom, C., Sandholm, N., Parkkonen, M., Tarnow, L., Parving, H.-H., McKnight, A. J., Maxwell, A. P., Cooper, M. E., et al. (2011) · Diabetes · doi:10.2337/db11-0073 · Cited by 70
Self-citationTherapeutic potential of pro-resolving mediators in diabetic kidney disease
Vartak, T., Godson, C., & Brennan, E. P. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.113965 · Cited by 72
Forsblom, C., Thomas, M. C., Moran, J., Saraheimo, M., Thorn, L., Wadén, J., Gordin, D., Frystyk, J., Flyvbjerg, A., Groop, P.-H., et al. (2011) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2011.02406.x · Cited by 69
Self-citationWaist-height ratio and waist are the best estimators of visceral fat in type 1 diabetes
Parente, E. B., Mutter, S., Harjutsalo, V., Ahola, A. J., Forsblom, C. M., & Groop, P. (2020) · Scientific Reports · doi:10.1038/s41598-020-75667-5 · Cited by 76
Self-citationPrevention of Cardiovascular Disease in Type 1 Diabetes
Manrique‐Acevedo, C., Hirsch, I. B., & Eckel, R. H. (2024) · New England Journal of Medicine · doi:10.1056/nejmra2311526 · Cited by 79
Aschner, P. J., Horton, E., Leiter, L. A., Munro, N. M., Skyler, J. S., & Management*, O. B. O. T. G. P. F. E. D. (2010) · International Journal of Clinical Practice · doi:10.1111/j.1742-1241.2009.02296.x · Cited by 76
Diabetic kidney disease in children and adolescents
Afkarian, M. (2014) · Pediatric Nephrology · doi:10.1007/s00467-014-2796-5 · Cited by 71
on behalf of the FinnDiane Study Group, Wadén, J., Tikkanen-Dolenc, H., Forsblom, C. M., Harjutsalo, V., Thorn, L. M., Saraheimo, M., Tolonen, N., Rosengård‐Bärlund, M., Gordin, D., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3499-6 · Cited by 76
Self-citationWang, K., Zheng, X., Pan, Z., Yao, W., Gao, X. Y., Wang, X., & Ding, X. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.00559 · Cited by 65
“MDA, an end-product of lipid peroxidation, directly reflect the extent of lipid peroxidation (Huang et al., 2013).”
BackgroundProteases and Protease Inhibitors of Urinary Extracellular Vesicles in Diabetic Nephropathy
Musante, L., Tataruch, D., Gu, D., Liu, X., Forsblom, C. M., Groop, P., & Holthöfer, H. (2015) · Journal of Diabetes Research · doi:10.1155/2015/289734 · Cited by 68
Self-citationPenno, G., Solini, A., Bonora, E., Orsi, E., Fondelli, C., Zerbini, G., Trevisan, R., Vedovato, M., Cavalot, F. L., Laviola, L., et al. (2018) · Acta Diabetologica · doi:10.1007/s00592-018-1133-z · Cited by 69
“Data from the general population [11–14] and patients with type 1 [15, 16] and type 2 [17, 18] diabetes showed that albuminuria and reduced eGFR are independently associated with all-cause and CVD mortality.”
BackgroundThe serum uric acid concentration is not causally linked to diabetic nephropathy in type 1 diabetes
Ahola, A. J., Sandholm, N., Forsblom, C. M., Harjutsalo, V., Dahlström, E. H., & Groop, P. (2017) · Kidney International · doi:10.1016/j.kint.2016.11.025 · Cited by 66
Self-citationKramer, H., Boucher, R. E., Leehey, D. J., Fried, L. F., Wei, G., Greene, T., Rosas, S. E., Cooper, R., Cao, G., & Beddhu, S. (2018) · Diabetes Care · doi:10.2337/dc17-1954 · Cited by 67
Diabetic nephropathy in type 1 diabetes: has the outlook improved since the 1980s?
Marshall, S. M. (2012) · Diabetologia · doi:10.1007/s00125-012-2606-1 · Cited by 66
Thomas, A. A., Feng, B., & Chakrabarti, S. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00268.2017 · Cited by 62
Non-Proteinuric Diabetic Nephropathy
Robles, N. R., Villa, J., & Gallego, R. H. (2015) · Journal of Clinical Medicine · doi:10.3390/jcm4091761 · Cited by 67
“diabetes with a duration longer than five years, the presence of sustained microalbuminuria is typically associated with the development of diabetic nephropathy [12].”
BackgroundVelho, G., Boustany, R. E., Lefèvre, G., Mohammedi, K., Fumeron, F., Potier, L., Bankir, L., Bouby, N., Hadjadj, S., Marre, M., et al. (2016) · Diabetes Care · doi:10.2337/dc16-1003 · Cited by 67
Glycaemic control and excess risk of major coronary events in persons with type 1 diabetes
Matuleviciene-Anängen, V., Rosengren, A., Svensson, A.-M., Pivodic, A., Gudbjörnsdottir, S., Wedel, H., Kosiborod, M., Haraldsson, B., & Lind, M. (2017) · Heart · doi:10.1136/heartjnl-2016-311050 · Cited by 61
Hadjadj, S., Cariou, B., Fumeron, F., Gand, E., Charpentier, G., Roussel, R., Kasmi, A.-A., Gautier, J., Mohammedi, K., Gourdy, P., et al. (2015) · Diabetologia · doi:10.1007/s00125-015-3785-3 · Cited by 66
“In type 1 diabetes, the presence of diabetic nephropathy is associated with increased mortality risk, while non-nephropathic individuals have a more favourable life expectancy [2, 3].”
BackgroundPredicting major outcomes in type 1 diabetes: a model development and validation study
Soedamah‐Muthu, S. S., Vergouwe, Y., Costacou, T., Miller, R. G., Zgibor, J. C., Chaturvedi, N., Snell‐Bergeon, J. K., Maahs, D. M., Rewers, M., Forsblom, C. M., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3358-x · Cited by 63
“More importantly, the presence of nephropathy is associated with a substantially increased risk of premature death [13].”
BackgroundSelf-citationTowards understanding the inherited susceptibility for nephropathy in diabetes
Thomas, M. C., Groop, P., & Tryggvason, K. (2012) · Current Opinion in Nephrology & Hypertension · doi:10.1097/mnh.0b013e328350313e · Cited by 62
“Unau Health | Lippincott Williams & Wilk mortality associated with diabetes is almost entirely confined to those with nephropathy [10,11].”
BackgroundSelf-citationTikellis, C., Pickering, R., Tsorotes, D., Du, X.-J., Kiriazis, H., Nguyen-Huu, T.-P., Head, G. A., Cooper, M. E., & Thomas, M. C. (2012) · Clinical Science · doi:10.1042/cs20110668 · Cited by 57
Self-citationRenin-angiotensin-aldosterone system activation in long-standing type 1 diabetes
Lovshin, J. A., Boulet, G., Lytvyn, Y., Lovblom, L. E., Bjornstad, P., Farooqi, M. A., Lai, V., Cham, L., Tse, J., Orszag, A., et al. (2018) · JCI Insight · doi:10.1172/jci.insight.96968 · Cited by 56
Metabolomic Profile Predicts Development of Microalbuminuria in Individuals with Type 1 Diabetes
Haukka, J. K., Sandholm, N., Forsblom, C., Cobb, J. E., Groop, P.-H., & Ferrannini, E. (2018) · Scientific Reports · doi:10.1038/s41598-018-32085-y · Cited by 56
Self-citationLi, J., Guo, K., Qiu, J., Xue, S., Pi, L., Li, X., Huang, G., Xie, Z., & Zhou, Z. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003428 · Cited by 61
Pavkov, M. E., Knowler, W. C., Hanson, R. L., Williams, D. E., Lemley, K. V., Myers, B. D., & Nelson, R. G. (2013) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2012.11.044 · Cited by 54
The Promise of Mesenchymal Stem Cell Therapy for Diabetic Kidney Disease
Griffin, T. P., Martin, W. P., Islam, M. N., O’Brien, T., & Griffin, M. D. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0734-6 · Cited by 55
Novel insights into the disease transcriptome of human diabetic glomeruli and tubulointerstitium
Levin, A., Reznichenko, A., Witasp, A., Liu, P., Greasley, P. J., Sorrentino, A., Blöndal, T., Zambrano, S. S., Nordström, J., Bruchfeld, A. N., et al. (2020) · Nephrology Dialysis Transplantation · doi:10.1093/ndt/gfaa121 · Cited by 56
Piscitelli, P., Viazzi, F., Fioretto, P., Giorda, C., Ceriello, A., Genovese, S., Russo, G., Guida, P., Pontremoli, R., & De Cosmo, S. (2017) · Scientific Reports · doi:10.1038/s41598-017-03551-w · Cited by 52
Clinical and pathological factors associated with progression of diabetic nephropathy
Liang, S., Cai, G., & Chen, X. (2017) · Nephrology · doi:10.1111/nep.13182 · Cited by 55
Molecular form and concentration of serum α2-macroglobulin in diabetes
Yoshino, S., Fujimoto, K., Takada, T., Kawamura, S., Ogawa, J., Kamata, Y., Kodera, Y., & Shichiri, M. (2019) · Scientific Reports · doi:10.1038/s41598-019-49144-7 · Cited by 59
Harjutsalo, V., Thomas, M. C., Forsblom, C., Groop, P., & On Behalf of the FinnDiane Study Group (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13456 · Cited by 53
Self-citationThe Complement Pathway: New Insights into Immunometabolic Signaling in Diabetic Kidney Disease
Tan, S. M., Snelson, M., Østergaard, J. A., & Coughlan, M. T. (2021) · Antioxidants and Redox Signaling · doi:10.1089/ars.2021.0125 · Cited by 55
“Individuals with DKD carry a higher risk of developing comorbidities such as cardiovascular disease and, indeed, renal dysfunction is the major predictor of all-cause mortality in both type 1 diabetes (T1D) and type 2 diabetes (T2D) (3, 51).”
BackgroundGenome-wide association study of urinary albumin excretion rate in patients with type 1 diabetes
Sandholm, N., on behalf of the FinnDiane Study Group, Forsblom, C. M., Mäkinen, V., McKnight, A. J., Österholm, A.-M., He, B., Harjutsalo, V., Lithovius, R., Gordin, D., et al. (2014) · Diabetologia · doi:10.1007/s00125-014-3202-3 · Cited by 56
“Moreover, individuals with type 1 diabetes and even modest amounts of albuminuria have an increased risk of premature mortality [4].”
BackgroundSelf-citationWong, J., Constantino, M., & Yue, D. K. (2014) · Current Diabetes Reports · doi:10.1007/s11892-014-0566-1 · Cited by 53
Forsblom, C. M., Moran, J. L., Harjutsalo, V., Loughman, T., Wadén, J., Tolonen, N., Thorn, L. M., Saraheimo, M., Gordin, D., Groop, P., et al. (2014) · Diabetes Care · doi:10.2337/dc14-0225 · Cited by 54
Self-citationDiabetes, Kidney Disease, and Cardiovascular Outcomes in the Jackson Heart Study.
Afkarian, M., Katz, R., Bansal, N., Correa, A., Kestenbaum, B., Himmelfarb, J., de Boer, I., & Young, B. (2016) · American Society of Nephrology. Clinical Journal · doi:10.2215/cjn.13111215 · Cited by 46
Putaala, J., Haapaniemi, E., Gordin, D., Liebkind, R., Groop, P., Kaste, M., & Tatlisumak, T. (2011) · Stroke · doi:10.1161/strokeaha.110.612721 · Cited by 50
Self-citationZambrowicz, B., Lapuerta, P., Strumph, P., Banks, P. L., Wilson, A., Ogbaa, I., Sands, A., & Powell, D. R. (2014) · Clinical Therapeutics · doi:10.1016/j.clinthera.2014.10.026 · Cited by 51
Transforming growth factor β (TGFβ) and related molecules in chronic kidney disease (CKD)
Huynh, P., & Chai, Z. (2019) · Clinical Science · doi:10.1042/cs20180438 · Cited by 54
Afkarian, M., Polsky, S., Parsa, A., Aronson, R., Caramori, M. L., Cherney, D. Z. I., Crandall, J. P., de Boer, I. H., Elliott, T. G., Galecki, A. T., et al. (2019) · Diabetes Care · doi:10.2337/dc19-0342 · Cited by 50
Forbes, J. M., Söderlund, J., Yap, F. Y. T., Knip, M., Andrikopoulos, S., Ilonen, J., Simell, O., Veijola, R., Sourris, K. C., Coughlan, M. T., et al. (2011) · Diabetologia · doi:10.1007/s00125-011-2058-z · Cited by 52
“study group [23] are provided in Table 1.”
BackgroundSelf-citationSKUPIEN, J. K., Smiles, A. M., Valo, E., Ahluwalia, T. S., Gyorgy, B., Sandholm, N., Croall, S., Lajer, M., McDonnell, K., Forsblom, C. M., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1369 · Cited by 49
Self-citationCould IL-17A Be a Novel Therapeutic Target in Diabetic Nephropathy?
Lavoz, C., Rayego‐Mateos, S., Orejudo, M., Opazo-Ríos, L., Marchant, V. A., Márquez‐Expósito, L., Tejera‐Muñoz, A., Navarro‐González, J. F., Droguett, A., Ortíz, A., et al. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010272 · Cited by 51
The Genetics of Diabetic Nephropathy
Brennan, E. P., McEvoy, C. M., Sadlier, D. M., Godson, C., & Martin, F. (2013) · Genes · doi:10.3390/genes4040596 · Cited by 52
“microvascular complications, the larger blood vessels become atherosclerotic and the risk for cardiovascular disease is 2–3 times higher compared to people without diabetes [1–3].”
BackgroundGagnum, V., Stene, L. C., Leivestad, T., Joner, G., & Skrivarhaug, T. (2017) · Diabetes Care · doi:10.2337/dc16-1213 · Cited by 44
Gagnum, V., Saeed, M., Stene, L. C., Leivestad, T., Joner, G., & Skrivarhaug, T. (2017) · Diabetes Care · doi:10.2337/dc17-0906 · Cited by 46
Sigfrids, F. J., Groop, P., & Harjutsalo, V. (2022) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(22)00099-7 · Cited by 46
Self-citationMaahs, D. M., Jalal, D., Chonchol, M., Johnson, R. J., Rewers, M., & Snell-Bergeon, J. K. (2013) · Diabetes Care · doi:10.2337/dc12-2538 · Cited by 44
“This contrast between the CACTI data and the previous reports (5,6) may be explained by the use of a surrogate marker of coronary artery disease that captures earlier subclinical atherosclerotic change, whereas even with 7 and 20 years of follow-up the excess risk for CVD in people with type 1 diabetes may not be mani…”
BackgroundResultInfluentialBody Mass Index and Mortality in Individuals With Type 1 Diabetes
Dahlström, E. H., Sandholm, N., Forsblom, C. M., Thorn, L. M., Sigfrids, F. J., Harjutsalo, V., & Groop, P. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2019-00042 · Cited by 48
Self-citationReutens, A. T., Jandeleit-Dahm, K. A. M., Thomas, M. C., Salim, A., Livera, A. M. D., Bach, L. A., Colman, P. G., Davis, T. M. E., Ekinci, E. I., Fulcher, G., et al. (2019) · Contemporary Clinical Trials · doi:10.1016/j.cct.2019.105892 · Cited by 47
Self-citationGordin, D., Wadén, J., Forsblom, C., Thorn, L., Rosengård-Bärlund, M., Tolonen, N., Saraheimo, M., Harjutsalo, V., Groop, P.-H., & for the FinnDiane Study Group (2011) · Diabetes Care · doi:10.2337/dc10-2013 · Cited by 46
Self-citationIs the Risk and Nature of CVD the Same in Type 1 and Type 2 Diabetes?
Duca, L. M., Sippl, R., & Snell‐Bergeon, J. K. (2013) · Current Diabetes Reports · doi:10.1007/s11892-013-0380-1 · Cited by 50
Changing Impact of Modifiable Risk Factors on the Incidence of Major Outcomes of Type 1 Diabetes
Miller, R. G., Secrest, A. M., Ellis, D., Becker, D. J., & Orchard, T. J. (2013) · Diabetes Care · doi:10.2337/dc13-1142 · Cited by 44
Marcovecchio, M. L., Chiesa, S. T., Armitage, J., Daneman, D., Donaghue, K. C., Jones, T. W., Mahmud, F. H., Marshall, S. M., Neil, H. A. W., Dalton, R. N., et al. (2018) · Diabetes Care · doi:10.2337/dc18-1125 · Cited by 44
“Microalbuminuria has been recognized for a long time as a hallmark of DN and a predictor of CVD in people with type 1 diabetes (4,5).”
BackgroundSinclair, A. J., Dunning, T. L., Dhatariya, K., & an International Group of Experts (2019) · Diabetic Medicine · doi:10.1111/dme.14135 · Cited by 44
Groop, P., Thomas, M. C., Feodoroff, M., Forsblom, C. M., & Harjutsalo, V. (2018) · Diabetes Care · doi:10.2337/dc17-1618 · Cited by 47
Self-citationBarlovič, D. P., Harjutsalo, V., Gordin, D., Kallio, M., Forsblom, C. M., King, G. L., & Groop, P. (2018) · Diabetes Care · doi:10.2337/dc18-0476 · Cited by 46
Self-citationBarlovič, D. P., Tikkanen-Dolenc, H., & Groop, P. (2019) · Current Diabetes Reports · doi:10.1007/s11892-019-1157-y · Cited by 45
Self-citation
Metadata
- Authors
- Groop, P.-H., Thomas, M. C., Moran, J. L., Wadèn, J., Thorn, L. M., Mäkinen, V.-P., Rosengård-Bärlund, M., Saraheimo, M., Hietala, K., Heikkilä, O., & Forsblom, C.
- Affiliations
- Helsinki University Hospital (FI)
- Baker Heart and Diabetes Institute (AU)
- Department of Intensive Care Medicine, The Queen Elizabeth Hospital, Woodville, South Australia, Australia;
- Folkhälsan Institute of Genetics, Folkhälsan Research Center, Biomedicum Helsinki, Helsinki, Finland;
- Corresponding author
- Groop, Per-Henrik
- ORCID
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2009-04-28
- Volume
- 58
- Issue
- 7
- Pages
- 1651-1658
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2699848
- OpenAlex
- W2101457616
- Semantic Scholar
- 8c94474962d440b785728afdfb3a4ed830eedf9d
- Cited by
- 638
- References
- 49
- Citations by year
- 2026: 14 · 2025: 29 · 2024: 30 · 2023: 38 · 2022: 59 · 2021: 43 · 2020: 40 · 2019: 48 · 2018: 55 · 2017: 43 · 2016: 40 · 2015: 41 · 2014: 54 · 2013: 40 · 2012: 23
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion, cc-by-nc-nd)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- Funders
- Wilhelm och Else Stockmanns Stiftelse
- European Commission
- Signe ja Ane Gyllenbergin Säätiö
- Waldemar von Frenckells Stiftelse
- Topics
- Health Sciences › Medicine › Nephrology › Chronic Kidney Disease and Diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- type 1 diabetes, chronic kidney disease, all-cause mortality, diabetic nephropathy, albuminuria, microalbuminuria, macroalbuminuria, end-stage renal disease, glomerular filtration rate, hyperfiltration, standardized mortality ratio
- MeSH terms
- Adolescent, Adult, Cause of Death, Diabetes Mellitus, Type 1, Diabetic Nephropathies, Female, Finland, Follow-Up Studies, Glomerular Filtration Rate, Humans, Insulin, Male, Middle Aged, Severity of Illness Index, Cohort Studies, Age of Onset, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.